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Summary Placental and placental-like alkaline phosphatase (PLAP) levels in the culture media of 87 cell lines
of neoplastic and 'normal' origin were measured by a conventional immunosorbent enzymatic assay (IAEA)
and by a new immunoradiometric assay (IRMA). The IRMA detected immunoreactive PLAP in 37 of 80
(46%) human epithelial and germ cell cultures, while the IAEA detected PLAP in only 25 (33%). Of the 52
non-germ cell tumour cultures, the IRMA detected expression in 24 (46%) and the IAEA in only 16 (31%). In
17 cases (21 %) the IRMA recorded levels double that of the IAEA, while in five cultures (6%) the reverse was
true. The IRMA was much more robust than the IAEA and had considerably lower inter- and intra-assay
coefficients of variation (3.75-8.5% vs 5.2-46%). Detection of PLAP(-like) expression by IAEA is dependent
on neoplastic expression of enzymically functional molecules and quantification assumes constant enzyme
kinetics. PLAP-like material has a higher catalytic rate constant than PLAP and thus will give higher values
on a stoichiometric basis in an IAEA. The higher detection rate and levels of PLAP-like material in neoplastic
cultures when measured by the IRMA clearly demonstrate ectopic expression of non-enzymatic PLAP and
PLAP-like genes. The incidence of PLAP(-like) expression by non-germ cell and possible germ cell tumours
has been underestimated and its utility as a tumour marker should be re-examined using assays which measure
antigen mass rather than phosphatase activity.
The tissue-specific alkaline phosphatase family consists of at
least three variants, each encoded by separate genes (Martin
et al., 1990). These variants are placental alkaline phospha-
tase (PLAP), germ cell alkaline phosphatase (PLAP-like) and
intestinal alkaline phosphatase (IAP). All have been mapped
to a gene cluster at human chromosome 2q34-q37 (Griffin et
al., 1987; Martin et al., 1990; Millan & Manes, 1988). Tissue
non-specific alkaline phosphatase, also referred to as liver/
kidney/bone type, is not a member of this cluster and is
coded on the short arm of chromosome 1 (Stigbrand &
Fishman, 1984).
Placenta-specific alkaline phosphatase (PLAP) is a mem-
brane-bound protein of the placental syncytiotrophoblast. It
is a dimer consisting of two identical subunits and has no
transmembrane domains. Anchorage to the external side of
the plasma membrane is via a glycan-phosphatidylinositol
moiety. The function of PLAP is to bind maternal immuno-
globulin G (IgG) and transport this protein across the
placental barrier. The non-physiological phosphatase activity
(pH optimum 10.5, temperature optimum 65°C) is considered
to be a secondary reaction of this process (Makiya & Stig-
brand, 1992).
Ectopic expression of this placental antigen by cancers has
been recognised for many years. In particular, seminomatous
and non-seminomatous testicular germ cell tumours express
the germ cell (PLAP-like) isoform. The placental variant is
also expressed by some lung and cervix tumours.
Most assays for PLAP and PLAP-like antigens rely on the
intrinsic alkaline phosphatase activity of the molecule.
Specific antibodies have been raised against PLAP, which
also recognise the 98% homologous PLAP-like variant.
These are commonly used for immunosorption of PLAP(-
like) molecules onto reaction wells prior to measurement of
phosphatase activity. However, this format may be inappro-
priate for the detection of ectopic expression of PLAP.
Enzymic activity may deteriorate with storage. Furthermore,
neoplastic expression of PLAP and PLAP-like genes may
result in incomplete and thus non-active forms of the
molecule.
We have developed a two-site immunoradiometric assay to
measure PLAP and PLAP-like material. We have determined
the levels in culture media of 88 cell lines of neoplastic and
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'normal' origin. The results have been compared with those
obtained by the commonly used immunosorbent enzymatic
assay (IAEA) (McLoughlin et al., 1983).
Materials and methods
Assay for PLAP
PLAP was measured using an enzymatic immunosorbent
assay (IAEA) and an in-house immunoradiometric assay
(IRMA).
The IAEA was an adaptation of the assay method of
McLaughlin et al. (1983). Monoclonal antibody H 1 7E2
(Travers & Bodmer, 1984) (donated by A. Badley, Unilever
Research, Colworth Laboratory, Sharnbrook, Bedfordshire,
UK) was absorbed onto the wells of microtitre plates. These
were preincubated with serum samples or standards, and
levels of captured PLAP and PLAP-like material were deter-
mined by colorimetric measurement of the endogenous phos-
phatase activity (Figure lb). The activity in samples was
compared with standards derived from serial dilution of
highly purified PLAP (750IUmg-' Calzyme Laboratories,
San Luis Obispo, CA, USA). The detection limit was
0.18 IU l' and the inter- and intra-assay variation were
10-46% and 5.2-13% respectively.
The in-house IRMA for PLAP utilised a monoclonal anti-
body H7 (InRo BioMedTek, Umea, Sweden) coupled to
1,l-carbonyldiimidazole-activated cellulose (SCIPAC, Sitting-
bourne, Kent, UK) as solid phase. Monoclonal antibody
H17E2 radiolabelled with iodine-125 by the chloramine T
method was used for detection (see Figure lc). Binding was
compared with standards of purified PLAP as for the IAEA.
Monoclonal antibody H7 recognises epitopes on PLAP close
to the glycan-phosphatidylinositol membrane linkage, while
H17E2 recognises epitopes on the exposed surface which are
separate from the active site of the enzyme (Hoylaert &
Milan, 1991) (see Figure la). The detection limit of this assay
was 0.1 IU 1' and there was a moderate hook effect. For
comparison with the IAEA a cut-off of 0.18 IU I` was used.
Intestinal alkaline phosphatase and tissue non-specific
alkaline phosphatase (extracted from liver and bone; Cal-
zyme Laboratories) did not cross-react at concentrations as
high as 100 IU 1'. The inter-assay variation was 3.75-8.5%
and the intra-assay variation 3.86-5.35%.
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Figure 1 a, Diagrammatic representation of placental alkaline phosphatase (PLAP), indicating the sites responsible for phos-
phatase activity, IgG Fc binding and linkage to the plasma membrane (via a phosphatidylinositol moiety). The relationship of these
sites to the antigenic epitopes defined by monoclonal antibodies H17E2 and H7 is also shown. b, Schematic representation of the
immunosorbent enzymatic assay (IAEA) for placental alkaline phosphatase (PLAP). (1) Anti-PLAP monoclonal antibody (MCA)
H17E2 is absorbed onto microtitre plate wells. (2) PLAP present in samples is captured by absorbed MCA H17E2. (3) After
washing a colourless cromogen is added in alkaline conditions (pH 10) and converted to a yellow product by endogenous activity
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Cell lines
Culture media from 87 established and finite cell lines were
examined. These included 17 bladder carcinomas, four breast
carcinomas, 11 cervical carcinomas, three choriocarcinomas,
two colorectal carcinomas, eight testicular germ cell tumours,
five epithelial ovarian cancers, eight squamous cell (SCC) or
epidermoid cancers (EC) of the oral and respiratory tract,
one vulval tumour and one Wilms tumour (kidney). Culture
media from eight normal urothelia and seven skin keratino-
cyte preparations were also assayed, together with media
from three human and four murine control lines. Most of
these cell lines are described in an earlier study (Iles et al.,
1990). Additional media from cultured bladder carcinoma
were provided by M. Knowles (Marie Curie Institute, Oxted,
Surrey, UK). Additional cervical cancer cell line clones were
originated by X. Han and E. Heyderman (St Thomas's Hos-
pital, London, UK) (see Table I). In all cases the cells were
grown to confluence in culture flasks (75 cm2 adherence area).
At this stage the medium (10 ml) was exchanged and the
culture continued for a further 96 h. The medium was then
harvested and stored at - 20°C until assayed.
Results
The cell lines and the levels of PLAP/PLAP-like immuno-
reactivity and enzymic activity present in the culture media
are shown in Table I. All seven control cultures had unde-
tectable levels of PLAP-like immunoreactivity or enzyme
activity. The IRMA detected immunoreactive PLAP(-like)
material in media from 37 of the 80 human cell lines (46%).
The IAEA detected PLAP(-like) activity in 25 of these media
(33%). In 17 cultures (21%) PLAP levels measured by
IRMA were higher than (more than double) those measured
by IAEA, while in five cultures (6%) the reverse was true. In
13 cultures (16%) PLAP was detectable by IRMA but not by
the IAEA. The converse was true in only one culture (1%).
The incidence of positive findings for cultures of specific
tissues/neoplasms was: 8/17 bladder carcinoma, 0/4 breast
carcinoma, 5/11 cervical carcinoma, 3/3 choriocarcinoma,
2/2 colorectal, 5/8 testicular germ cell, 1/5 epithelial ovarian,
7/8 oral and respiratory epithelial carcinoma (EC) and
squamous cell carcinoma (SCC), 0/2 small-cell lung car-
cinoma, 0/1 Wilms tumour and 1/1 vulval carcinoma cell
lines. Additionally, 3/8 normal skin keratinocyte, 2/7 normal
urothelial and 0/3 oral mucosal cell lines were found to have
detectable levels of PLAP(-like) antigen in their culture
media. None of three human fibroblast control or four
murine carcinoma/fibroblast control cell lines had detectable
levels of PLAP(-like) antigen in their culture media.
Discussion
Ectopic expression of PLAP, and in particular the homo-
logous germ cell alkaline phosphatase (PLAP-like), has been
used as a marker of testicular and ovarian germ cancers
(Nathason & Fishman, 1971). Expression by testicular semin-
omas and ovarian dysgerminomas might provide a clinical
marker of these tumours; they rarely produce human chori-
onic gonadotrophin (hCG) and never produce alpha-feto-
protein (AFP) (Horwich et al., 1985; Tucker et al., 1985;
Lange et al., 1982). However, some have reported that
measurement of PLAP(-like) levels is of little or no clinical
value (Nielson et al., 1990; Munro et al., 1991). Elevated
PLAP or PLAP-like activity has also been found in the
serum of patients with lung, colorectal and urogenital car-
cinomas (Fishman et al., 1968; Stigbrand et al., 1982).
PLAP(-like) expression had been demonstrated in extracts
from cervical, colorectal, bladder and choriocarcinoma cell
lines (Nozawa & Fishman, 1982).
Most assays for PLAP and PLAP-like material take
advantage of the intrinsic alkaline phosphatase activity for
detection and quantification. Recently, Makiya and Stig-
brand (1992) have shown that PLAP binds IgG via the Fc
portion of the molecule; PLAP appears to be responsible for
transport of maternal IgG across the placenta. It seems likely
that all members of the alkaline phosphatase family are
transmembrane transport molecules (Makiya, 1992). Neo-
plastic expression of the PLAP and PLAP-like genes may
yield incomplete and therefore non-enzymatic forms of the
molecule. We have previously shown that many non-tropho-
blastic, non-endocrine carcinomas express incomplete and
therefore non-bioactive human chorionic gonadotrophin (Iles
et al., 1990a). Bladder cancers secrete immunoreactive hCG
in vivo (30% of all cases) and in vitro (70% of cell lines).
However, this is almost entirely expression of the free beta-
subunit, which has no gonadotrophic activity (Iles & Chard,
1989; Iles et al., 1990b).
Here we demonstrate that immunoreactive PLAP(-like)
material is released into the culture media of 37 of 80
epithelial cell lines. Using an established IAEA only 26 of the
cell lines were so detected. In most cases levels were higher in
the immunoassay than in the enzymatic assay. IRMAs are
generally more robust than enzymic assays and the intra- and
inter-assay coefficients of variation were considerably lower
for the PLAP IRMA. The current UK External Quality
Assurance Scheme (UKEQUAS) shows a 10-68% coefficient
of variation in the estimation of serum PLAP levels by
different laboratories using the IAEA methods (UKEQUAS,
Department of Immunology, Royal Hallamshire Hospital,
Sheffield, UK).
In the present study five culture media had higher levels of
PLAP when measured by the enzymic assay. These cell lines
were of germ cell origin or known to express the germ
cell/PLAP-like alkaline phosphatase gene (KB, Hep2)
(Nozawa & Fishman, 1982; Luduena & Sussman, 1976).
There is a high degree of homology between placental and
germ cell alkaline phosphatase, and both are recognised by
H7 and H17E2 antibodies (Milan & Stigbrand, 1983; Travers
& Bodmer, 1984). Thus antigenic variation is not likely to
account for the differences in assay estimation of PLAP/
PLAP-like levels. The seven amino acid substitutions found
in the PLAP-like isoform result in a higher catalytic rate
constant (Watanbe et al., 1991; Hoylaerts et al., 1992). Thus,
on a stoichiometric basis PLAP-like material will give higher
values than the authentic placental isoform when measured
by an enzymatic assay.
Immunoreactive PLAP(-like) material was found to be
expressed by a number of cell types, in particular testicular
germ cell tumours, choriocarcinomas, squamous cell and
epidermoid carcinomas of the oral and respiratory tract,
cervical and bladder cancers. Since high levels of enzymatic
PLAP were also found in the culture media from testicular
germ cell cancers it is likely that this material is the germ cell,
PLAP-like, isoform. It is interesting to note that all but two
of these lines (WG007 and PJ007) had originated from non-
seminomatous testicular tumours which no longer secrete
hCG or AFP in vitro (Iles et al., 1987).
For most of the remaining cultures, including the chorio-
carcinomas, immunoreactive levels exceeded enzymatic levels.
of the captured PLAP. (4) The reaction is terminated by the addition of acid and PLAP concentration determined as a function of
the measured OD at 405 nm. c, Diagrammatic representation of the immunoradiometric assay for PLAP. (1). Anti-PLAP MCA H7
is coupled to a solid phase of activated cellulose. (2) PLAP present in samples is captured by the solid phase bound MCA H7. (3)
125I-labelled MCA H17E2 binds to the PLAP via a sterically distant epitope and is captured to the solid phase. (4) The solid phase
is washed and precipitated and PLAP levels determined as a function of the radioactivity of the solid phase.
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Table I Placental alkaline phosphatase levels in tissue culture media
from neoplastic cell lines determined by immunoradiometric assay
(IRMA) and by immunosorbent enzymatic assay (IAEA)
IRMA measurement IAEA measurement of
Tissue of origin and of PLAP/PLAP-like PLAP/PLAP-like
cell line immunoreactivity activity
Malignant tissue
Bladder carcinoma
HDF
T24
RT4
J82
SCaBER
5637
JON
SW-800
253J
RTl 12
SW17
TccDES
5030
UM-UC-3
HCV-29
HT1 197
TccSUP
Breast carcinoma
MCF-7
BRCaPE
T47D
ZR-75-1
Cervical carcinoma
Hela
CaSKI
XH1A
XH1B
EH2A
EH2B
DE3H2
DE3H8
DE3H18
DE3H20
SM7
Choriocarcinoma
JAR
JEG-3
BeWo
Colorectal carcinoma
AJB
COLO-205
Testicular germ cell tumours
PJ077
TERA-1
HL
GH
TERA-2
WG007
833K
1618K
<0.18
<0.18
0.35
<0.18
3.35
0.36
<0.18
<0.18
<0.18
3.00
<0. 18
1.60
<0.18
<0.18
0.22
0.31
0.23
<0.18
<0.18
<0.18
<0.18
13.79
2.41
0.98
0.22
1.17
<0.18
<0.18
<0.18
<0.18
<0.18
<0.18
3.07
1.34
2.19
0.38
0.19
<0.18
0.73
14.92
3.58
<0.18
<0.18
7.95
6.67
Ovarian carcinoma
KOD <0.18
TR175 <0.18
SV-OV-3 0.30
1847 <0.18
TRI70 <0.18
EC and SCC of the oral and respiratory tract
KB 19.90
SCC25 0.19
SCC27 <0.18
HN-1-P 0.20
SCC4 1.34
SCC12B 1.14
Hep2 0.99
TR146 0.77
Small cell lung carcinoma
Highgate
Frey
Pocock
<0.18
<0.18
<0.18
<0.18
<0.18
<0.18
<0.18
1.56
0.46
<0.18
<0.18
<0.18
<0.18
<0.18
0.40
<0.18
<0.18
0.92
<0.18
<0.18
<0.18
<0.18
<0.18
<0.18
11.00
0.62
<0.18
<0.18
0.48
<0.18
<0.18
<0.18
<0.18
<0.18
<0.18
0.20
0.19
0.33
<0.18
<0.18
<0.18
3.67
14.59
6.23
<0.18
<0.18
2.20
9.24
<0.18
<0.18
0.33
0.26
<0.18
274.88
<0.18
<0.18
<0.18
0.37
0.26
7.30
0.29
<0.18
<0.18
<0.18
Table I Cont'd
IRMA measurement IAEA measurement of
Tissue of origin and of PLAP/PLAP-like PLAP/PLAP-like
cell line immunoreactivity activity
Wilms tumour
WTu0l3 <0.18 <0.18
Vulval carcinoma
A431 1.31 <0.18
Non-malignant tissues
Skin keratinocytes
HaCAT 1.14 0.62
SV/K14 0.22 <0.18
Fsk/mm <0.18 <0.18
Fsk/24/9 <0.18 <0.18
PSep <0.18 <0.18
UV/K14 0.27 <0.18
Fsk.D43 <0.18 <0.18
BSep.D41 <0.18 <0.18
Urothelium
NB/IB 0.86 0.37
NB/AJ <0.18 <0.18
HS0767 <0.18 <0.18
HU609 <0.18 <0.18
NB/Ul <0. 18 <0.18
NB/10 <0.18 <0.18
NB/JOH 0.92 <0.18
Oral mucosa
OrMuB <0.18 <0.18
OrMuC <0.18 <0.18
Controls
Murine carcinomas
Shinogi (epidermoid) <0.18 <0.18
BD4 (mammary) <0.18 <0.18
CD4 (rectal) <0.18 <0.18
Murine fibroblasts
3T3 <0.18 <0.18
Human fibroblasts
3AsubE (placental) <0.18 <0.18
FTF (fetal tissue) <0.18 <0.18
Malme 3 (dermis) <0.18 <0.18
Whether this is due to degradation of enzyme activity upon
storage or production of defective PLAP has yet to be deter-
mined. Our preliminary studies have shown that immuno-
reactive PLAP in the serum from various cancer patients can
consist of the dimeric and the monomeric forms. However,
there is considerable heterogeneity in the molecular size of
both forms. This could be due to variable glycosylation, a
truncated peptide sequence and, as has been shown for
PLAP produced by the KB cell line, expression of both
PLAP and PLAP-like (germ cell) genes resulting in a hybrid
dimer (Luduena & Sussman, 1976; R. Iles and T.E.J. Ind,
unpublished observations). Nevertheless, this study clearly
shows that the incidence of PLAP and PLAP-like gene ex-
pression by non-germ cell tumours has been underestimated.
Further application of purely immunometric PLAP assays
is warranted in order to re-evaluate PLAP as a tumour
marker not only of seminomas but of non-germ cell car-
cinomas. We have already demonstrated elevated serum
levels of immunoreactive PLAP in patients with malignant
pelvic disease (Ind et al., 1993a). Furthermore, aberrant levels
of PLAP have been shown to be associated with Down's
syndrome pregnancies when measured by this IRMA but not
by the IAEA (Brock et al., 1990; Ind et al., 1993b). Similarly,
we have demonstrated an association between PLAP levels
and blood groups which had not previously been recognised
(Ind et al., 1993c).
In conclusion, immunoreactive determination of PLAP and
PLAP-like levels may reflect the actual expression more
closely than determination based on phosphatase activity.
This may enhance the role of PLAP as an effective tumour
marker.
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